U.S. District Judge Zahid Quraishi denied Novo Nordisk’s bid for an emergency order to block Eli Lilly from airing advertisements comparing their competing weight-loss and diabetes treatments. The Trenton, New Jersey, federal judge ruled that Novo Nordisk failed to prove the commercial spots caused irreparable harm to its market share or corporate reputation.
In Plain English: The Clinical Takeaway
- Comparative Advertising: Eli Lilly’s television spots contrasted higher doses of its own medications against lower maintenance doses of rival therapies, sparking a legal battle over consumer perception.
- Prescription Stability: Court records showed that despite the disputed commercials airing between April and July, prescription rates for Novo Nordisk products remained steady.
- Ongoing Litigation: Monday’s decision addresses only the preliminary injunction; the broader federal lawsuit regarding false advertising and unfair competition remains active.
Legal Rejection Follows Two-Day August Hearing
The court’s decision follows a two-day evidentiary hearing held in late August, where lawyers for Novo Nordisk argued that advertisements for the obesity drug Zepbound and the diabetes treatment Mounjaro violated federal and state laws. Based on reporting from Reuters, the contested ads included a voiceover noting that Zepbound users achieved an average weight loss of 50 pounds (23 kg), compared to an average drop of 33 pounds (15 kg) for Wegovy users. A written disclaimer accompanied the claim.
A judge denies Novo Nordisk's ($NVO) request for a preliminary injunction in its lawsuit against Eli Lilly ($LLY), allowing Lilly to continue running GLP-1 advertisements during the legal proceedings.Novo Nordisk filed the suit in July, alleging that Lilly's marketing violates…
Novo Nordisk maintained that these head-to-head comparisons were inherently deceptive and unfair because they pitted higher doses of the two drugs against lower doses of Wegovy and Ozempic. Judge Quraishi, however, delivered a 25-page opinion concluding that the company’s witnesses, while credible, failed to demonstrate that the marketing campaign placed its sales at genuine risk or inflicted enduring damage in clinical settings. He characterized the claim of irreparable harm as inadequate to warrant the extraordinary relief of a court-ordered ban.
Market Dynamics and Financial Stakes
The underlying legal complaint, filed in July, highlights the intense commercial rivalry dominating the metabolic disease sector. Judicial documents show that sales of Ozempic combined with Novo Nordisk’s weight-loss medications reached approximately $32 billion over the course of 2025. The enterprise is working to win back a bigger share of the American market for its injectable treatments designed to reduce body weight.
Judge Quraishi noted in his ruling that if Novo Nordisk ultimately proves any nontrivial financial harm as the litigation proceeds, the company can be made whole through monetary damages rather than pre-trial censorship of its competitor’s advertising. Representatives for Indianapolis-based Eli Lilly welcomed the outcome, maintaining that the company has engaged in no unlawful marketing practices.
A spokesperson for Novo Nordisk emphasized in an email statement reported by Reuters that the court’s decision left the core question unresolved. While expressing disappointment over the denial of the injunction, the spokesperson underscored that the ruling did not determine whether Eli Lilly’s advertising practices are ultimately false and misleading.
References
- U.S. District Court for the District of New Jersey, Trenton. Novo Nordisk v. Eli Lilly and Company. Preliminary Injunction Ruling, Judge Zahid Quraishi.
- Reuters. “Judge denies Novo Nordisk bid to block Eli Lilly weight-loss drug ads.”
